Anthropic IPO coincides with analyst’s planned stock exit

Panmure Liberum analyst Joachim Klement plans to sell his U.S. and overseas stocks on Nov. 19 after the S&P 500 fell below its 200-day moving average.

Panmure Liberum analyst Joachim Klement plans to sell every stock in his personal portfolio at the end of European trading on Nov. 19. The plan followed the S&P 500’s fall below its 200-day moving average, the same day Anthropic began trading on Nasdaq.

Anthropic priced its initial public offering at $83 a share, above the top of its initial price range. The offering valued the Claude maker at $81.3 billion. The Nasdaq Composite rose 2% in early trading Thursday.

Klement’s rule uses the S&P 500’s average closing level over the previous 200 trading sessions to track the market’s direction. After the index fell below that average, he plans to shift his portfolio into long-term government bonds.

He plans to return to stocks if the S&P 500 rises above its 200-day average. Klement acknowledged that the signal could prove false. The index crossed its 200-day average more than 10 times around each of the previous market bubbles his team examined before losses accelerated.

“The Anthropic IPO doesn’t change my mind,” Klement said. His team is reviewing how much the largest cloud providers plan to spend in 2027, including whether lower spending forecasts could reduce orders for chip suppliers.

Klement cited Microsoft’s decision to reduce some deals with specialist cloud providers while placing more emphasis on data centers it builds itself. He expects 2027 spending forecasts could fall below investor expectations.

Panmure Liberum also reviewed Anthropic’s financial filings. The firm found that the company’s revenue growth was slowing while its computing costs were becoming harder to offset. The filings gave investors data to assess how efficiently Anthropic converts capital spending into sales.

For investors who want to remain exposed to equities, Panmure Liberum reviewed European stocks that held up during the 10 weakest sessions this year for Goldman Sachs’ Broad AI Basket. Its UK names included GSK, AstraZeneca, Unilever and Reckitt Benckiser.

The review covered 10 market declines and did not measure how the shares would perform during a prolonged downturn.

Articles by this author